Should you worry about your eyes if you take a GLP-1 drug?
Probably not, but the risk is worth understanding. This large Swedish study found that people taking a GLP-1 drug had a higher relative risk of sudden vision loss, yet the actual chance of it happening stayed very low. Over five years, about 0.12 percent of GLP-1 users developed this eye problem, compared with 0.07 percent of people taking a different diabetes drug.
GLP-1 drugs like semaglutide have become some of the most popular medicines in the world for diabetes and weight loss. So any hint of a serious side effect gets a lot of attention. This study looked at whether these drugs are linked to a rare condition called anterior ischemic optic neuropathy, a form of sudden and usually permanent vision loss.
What is anterior ischemic optic neuropathy?
Anterior ischemic optic neuropathy happens when blood flow to the optic nerve is suddenly cut off. The optic nerve carries signals from your eye to your brain. When it loses its blood supply, part of it can be damaged for good. People often notice vision loss in one eye when they wake up, and it does not usually come back.
The condition is rare, but it can be life-changing. That is why researchers wanted to know if a widely used class of drugs might be tied to it, even by a small amount.
What the data show
The researchers followed 107,518 adults who started a GLP-1 receptor agonist, such as semaglutide, between 2013 and 2024. They compared them with 185,898 adults who started an SGLT-2 inhibitor, another common diabetes drug, during the same years. Using a second diabetes drug as the comparison group helps make the two groups more alike.
GLP-1 users had a higher relative risk of sudden vision loss. The risk was about 1.9 times higher at one year and about 1.7 times higher at five years. Those numbers sound alarming on their own. But relative risk only tells you how two groups compare, not how likely the event actually is.
The absolute risk is the part that matters most for real people, and it stayed very low. Over five years, roughly 0.12 percent of GLP-1 users developed the condition, compared with 0.07 percent of the comparison group. In plain terms, this affected about one extra person out of every 2,000 over five years. The link was also weaker among people who were already taking metformin.
Dr. Kumar’s Take
I read a study like this and my first job is to keep the two kinds of risk straight in my own head. A relative risk of nearly two times sounds frightening, and headlines love that number. But the absolute risk here is tiny, roughly one in a thousand over five years. For most of my patients, the proven benefits of these drugs for blood sugar, weight, and heart health still outweigh a rare eye risk of this size.
I also want to be careful about what this study can and cannot prove. It is an observational study, not a trial where people are randomly assigned. That means we cannot be sure the drug caused the vision loss. Something else about the people who take GLP-1 drugs might explain part of the gap. The fact that the link got weaker in people on metformin is a hint that other factors may be at play. I think this is worth watching, not worth panicking over.
How strong is the evidence?
This study has real strengths. It is nationwide, so it covers a whole country rather than a small sample. It followed nearly 300,000 people for up to five years, which is a lot of data for a rare condition. Comparing GLP-1 users against SGLT-2 users is smart, because both groups have diabetes and similar reasons for treatment.
Still, the study cannot prove cause and effect. People who get one drug over another may differ in ways the researchers could not fully measure, a problem called confounding. The authors themselves urge cautious interpretation for this reason. Diabetes alone can harm the eyes and blood vessels, so untangling the drug’s role from the disease’s role is hard. This is strong signal-finding work, but it is not the final word.
Practical Takeaways
- If you take a GLP-1 drug, do not stop it on your own based on this study, since the absolute risk of vision loss is very low and these drugs offer proven benefits.
- Tell your doctor right away if you suddenly lose vision in one eye or notice a dark or blurry patch, especially first thing in the morning.
- If you already have eye problems or a history of optic nerve issues, ask your doctor whether extra eye monitoring makes sense for you.
- Remember that a higher relative risk is not the same as a high chance of harm, and ask your doctor to explain your personal risk in plain numbers.
Related Studies and Research
- Roald Dahl’s unlikely medical breakthroughs
- Biodiversity and drug discovery: why we’re losing one important medicine every two years
- The link between GLP-1 receptor agonists and worsening mental illness
- A plant-based diet lowered heart disease risk over 20 years
FAQs
Should I stop taking Ozempic or Wegovy because of this study?
No, and you should never stop a prescribed medicine based on a single news headline. This study found only a small increase in a rare condition, and it could not prove the drug was the cause. For many people, GLP-1 drugs deliver large benefits for blood sugar, weight, and heart health. If you are worried, the right move is to talk with the doctor who prescribed it, not to quit on your own.
What are the early warning signs of optic nerve damage?
The most common sign is sudden vision loss in one eye, often noticed when you wake up in the morning. Some people describe a dark curtain, a blurry area, or a missing patch in their field of view. It is usually painless, which can make it easy to brush off at first. Because damage to the optic nerve is often permanent, any sudden change in vision should be treated as an emergency and checked the same day.
Why do doctors trust the absolute risk more than the relative risk?
Relative risk tells you how two groups compare, but it hides how common or rare an event really is. A risk that doubles still barely matters if the starting point is close to zero, which is the case here. Absolute risk tells you the real chance that something will happen to you over time. In this study, that chance was about one to two people out of every thousand over five years, which puts the scary-sounding relative number in perspective.
Bottom Line
This large Swedish study links GLP-1 drugs to a small rise in the relative risk of sudden vision loss from optic nerve damage, but the real chance of it happening stays very low, near 0.12 percent over five years. Because this is an observational study, it cannot prove the drug is the cause, and the authors urge caution. For most people, the proven benefits of GLP-1 drugs still outweigh this rare risk, though it is a signal worth watching and worth discussing with your doctor.
